NEW YORK, NY / ACCESSWIRE / November 22, 2017 / U.S. markets closed at record highs on the strength of corporate earnings and a rally from the technology sector. The Dow Jones Industrial Average gained 0.69 percent to close at 23,590.83, while the S&P 500 Index jumped 0.65 percent to close at 2,599.03. The tech-heavy Nasdaq Composite Index spiked 1.06 percent to close at 6,862.48. A strengthening economy, solid corporate earnings and bets on tax reform have combined to help lift all three major indexes up between 16 percent and 27.5 percent for the year.

"Earnings season is winding down and, when you look back, most companies have beaten expectations and that's a positive for the market," said Adam Sarhan, CEO of 50 Park Investments.

RDI Initiates Coverage on:

MannKind Corporation
https://rdinvesting.com/news/?ticker=MNKD

TG Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=TGTX

MannKind Corporation's stock moved 2.21% lower Tuesday, to close the day at $3.10. The stock recorded a trading volume of 2,360,335 shares, which was below its three months average volume of 8,382,127 shares. In the last year, MannKind Corporation's shares have traded in a range of 0.67 - 6.96. The share price has gained 362.69% from its 52-week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $3.84 is greater than its 200-day moving average of $2.11. Shares of the company are trading at a Price to Earnings ratio of 2.34. Shares of MannKind Corporation have fallen roughly 24.57 percent in the past month and are down 2.62 percent year-to-date.

Access RDI's MannKind Corporation Research Report at:
https://rdinvesting.com/news/?ticker=MNKD

On Tuesday, shares in TG Therapeutics, Inc. recorded a trading volume of 2,491,612 shares, which was above the three months average volume of 1,238,480 shares. The stock ended the day 3.90% lower at 7.40. The share price has gained 80.49% from its 52-week low with a 52-week trading range of 4.10 - 15.35.The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $9.16 is below its 200-day moving average of $10.84. Shares of TG Therapeutics have fallen roughly 38.33 percent in the past month and are up 59.14 percent year-to-date.

Access RDI's TG Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TGTX

Our Actionable Research on MannKind Corporation (NASDAQ:MNKD) and TG Therapeutics, Inc. (NASDAQ:TGTX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com